anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Source Note

Component collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 110,355
Current window 40,321-40,350
Pages 3,679
Rows per page 30
Component: Source Noteclear collectionreset all
18 30 60

Component

40,321-40,350 of 110,355

filter-aware
14
Includes references to clinical trial data and expert commentary regarding cardiovascular and renal side effects of atrasentan.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The StruggleLoop · Pattern Hunter1 hit
15
The text explicitly alleges data tampering regarding Acute Kidney Injury (AKI) reporting in the SONAR study.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The StruggleLoop · Pattern Hunter1 hit
17
The slide uses a table to highlight inconsistent reporting of Acute Kidney Injury (AKI) across different study groups and provides a narrative critique of cardiac failure reporting.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller 1 hit
18
The slide uses Kaplan-Meier survival curves to illustrate the effects of Atrasentan on primary composite renal outcomes in different patient cohorts.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller 1 hit
19
The slide argues that the drug causes fluid retention and anemia, contradicting the trial's stated conclusions.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller 1 hit
20
The text argues that the omission of hematocrit data in the SONAR trial masks a hemodynamic effect that would undermine claims of renal improvement.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller 1 hit
21
The slide uses a callout box for trial results and follows with a critical analysis of anemia as a side effect.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller 1 hit
22
Includes extensive footnotes citing regulatory documents and investor call transcripts.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller 1 hit
23
Includes a table detailing orphan drug designation and marketing approval for Filspari (sparsentan).Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller 1 hit
24
This is a text-heavy research note page focusing on competitive critique and data skepticism.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller 1 hit
25
The slide critiques the visual representation of clinical trial data, specifically the 'time-distorting' nature of the x-axis in the provided graph.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller 1 hit
26
The slide highlights inconsistencies between SONAR study reports and FDA filings, suggesting data manipulation to favor the drug's safety profile.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller 1 hit
27
The slide uses a table of clinical trial results to illustrate a methodological critique of composite endpoints.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller 1 hit
28
The text focuses on statistical manipulation in clinical trial endpoints and discrepancies in patient count reporting between AFFINITY and ALIGN studies.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The VictoryLoop · Cost Of Inaction1 hit
29
The slide uses a 'villain critique' approach to undermine the credibility of the company's clinical trial reporting.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The VictoryLoop · Cost Of Inaction1 hit
30
The slide uses a combination of text-based argument and visual data (charts) to expose potential manipulation of clinical trial reporting.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The VictoryLoop · Cost Of Inaction1 hit
31
Includes critical commentary on the ALIGN trial and potential data obfuscation.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The VictoryLoop · Cost Of Inaction1 hit
34
Includes detailed diagrams of disease pathophysiology and clinical trial design.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller 1 hit
36
Data source identified as FDA SONAR data.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller 1 hit
02
This is a research note from Muddy Waters Research, acting as a short-seller report.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The MonsterLoop · The Reveal1 hit
03
This slide functions as a forensic accounting critique, highlighting specific instances of alleged financial misreporting.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The MonsterLoop · The Reveal1 hit
04
This is a text-heavy research note page focusing on accounting irregularities and investor behavior.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The StruggleLoop · The Reveal1 hit
06
Includes annotations translating key fields to English.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Loop · The Reveal1 hit
07
The slide details specific accounting irregularities regarding warrant valuation and cost reimbursements, supported by extensive footnotes referencing SEC filings.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Loop · The Reveal1 hit
08
The slide argues that certain revenue should be reported as net rather than gross, citing specific 10-K filings.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Loop · The Reveal1 hit
09
The slide uses a table to adjust reported revenue and then provides a qualitative argument citing FASB standards to challenge the company's accounting method.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The VictoryLoop · The Reveal1 hit
10
The slide highlights a discrepancy in accounting treatment between two joint ventures to suggest financial manipulation.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The VictoryLoop · Cost Of Inaction1 hit
02
The slide sets up a 'before/after' or 'reality vs. representation' critique typical of short-seller research notes.Vivion Investments · Carson Block
Research note Short seller Beat · Expose Contradiction1 hit
03
Uses hyperbolic language ('gulags') and external citation (The Guardian) to frame the property negatively.Vivion Investments · Carson Block
Research note Short seller 1 hit
07
Includes a specific highlight on Crowne Plaza London Heathrow in the footer.Vivion Investments · Carson Block
Research note Short seller 1 hit